This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients with moderate to severe psoriasis

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-014368-20

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objectives of this study are to evaluate the efficacy and safety of 2 SC dosing tiers of ustekinumab in the treatment of dolescent subjects 12 to 18 years of age with moderate to severe chronic plaque psoriasis.


Critère d'inclusion

  • Moderate to severe plaque-type psoriasis